Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
And It Could Spark An Economic Boom For Investors

RNAZ Insider Trading

Insider Ownership Percentage: 14.80%
Insider Buying (Last 12 Months): $23,000.00
Insider Selling (Last 12 Months): $0.00

TransCode Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at TransCode Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TransCode Therapeutics Share Price & Price History

Current Price: $0.86
Price Change: Price Increase of +0.4401 (104.84%)
As of 12/7/2022 04:28 PM ET

This chart shows the closing price history over time for RNAZ up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

TransCode Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2022Robert Michael DudleyCEOBuy20,000$1.15$23,000.00893,114View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for TransCode Therapeutics (NASDAQ:RNAZ)

16.07% of TransCode Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RNAZ by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

TransCode Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/13/2022Renaissance Technologies LLC19,600$25K0.0%N/A0.151%Search for SEC Filing on Google Icon
5/17/2022Worth Venture Partners LLC324,157$0.93M0.4%+9.7%2.498%Search for SEC Filing on Google Icon
4/21/2022K.J. Harrison & Partners Inc19,987$58K0.0%+24.9%0.155%Search for SEC Filing on Google Icon
2/4/2022Redmond Asset Management LLC88,010$0.22M0.1%N/A0.682%Search for SEC Filing on Google Icon
1/26/2022K.J. Harrison & Partners Inc16,000$41K0.0%N/A0.124%Search for SEC Filing on Google Icon
11/16/2021ACT Capital L.L.C.50,000$0.15M0.1%N/A0.387%Search for SEC Filing on Google Icon
11/16/2021National Asset Management Inc.25,000$75K0.0%N/A0.194%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Securities LLC33,314$100K0.0%N/A0.258%Search for SEC Filing on Google Icon
11/12/2021AIGH Capital Management LLC1,270,500$3.80M0.8%N/A9.845%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
TransCode Therapeutics logo
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA-based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Read More on TransCode Therapeutics

Today's Range

Now: $0.86
Low: $0.52
High: $1.16

50 Day Range

MA: $0.80
Low: $0.40
High: $1.23

52 Week Range

Now: $0.86
Low: $0.37
High: $3.13

Volume

1,677,167 shs

Average Volume

122,702 shs

Market Capitalization

$11.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Who are the company insiders with the largest holdings of TransCode Therapeutics?

TransCode Therapeutics' top insider shareholders include:
  1. Robert Michael Dudley (CEO)
Learn More about top insider investors at TransCode Therapeutics.
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
And It Could Spark An Economic Boom For Investors